SenzaGen

SenzaGen FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of SenzaGen (SENZA.ST) as of Oct 9, 2026 is 86.80 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 77.65 % — a change of 11.79% (higher).

FCF Conversion

86.80 %

YoY

11.79%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of SenzaGen is 2025 86.80 % . FCF Conversion Rate (FCF/EBITDA) of SenzaGen was 2024 77.65 % . It decreases by 11.79% higher compared to the previous year.

The SenzaGen FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
169.18 SEK
Jan 1, 2019
69.06 SEK
Jan 1, 2020
116.50 SEK
Jan 1, 2021
75.43 SEK
Jan 1, 2022
74.90 SEK
Jan 1, 2023
91.69 SEK
Jan 1, 2024
77.65 SEK
Jan 1, 2025
86.80 SEK
The SenzaGen FCF Conversion history
YEARFCF ConversionYoY
86.80 %+11.79%
77.65 %-15.31%
91.69 %+22.41%
74.90 %-0.70%
75.43 %-35.25%
116.50 %+68.70%
69.06 %-59.18%
169.18 %+3.67%
163.19 %+33.25%
122.47 %-45.66%
225.38 %-43.39%
398.09 %—
Access this data via the Eulerpool API

SenzaGen Stock analysis

What does SenzaGen do? SenzaGen AB is a Swedish biotechnology company that specializes in the development and marketing of innovative and reliable tests for assessing allergenicity. Founded in 2010 by leading experts from the academic and industry sectors, the company has become a significant player in the field of toxicology. Current methods for assessing allergenicity, such as asthma, eczema, and allergic reactions, are often inaccurate and require the use of animals, which is ethically questionable and expensive. SenzaGen AB has developed a wide range of tests based on biomolecular technologies that use human cells to assess the allergenic reactivity of chemicals and products. These tests are accurate, cost-effective, and meet the current requirements of regulatory authorities and the industry. The company is headquartered in Lund, Sweden, and currently employs about 20 people. SenzaGen AB is a leader in the development of in vitro methods for evaluating allergenicity and utilizes various platform technologies such as gene expression and proteomics analysis, as well as the use of immune cells and keratinocytes. SenzaGen AB's Microarray technology platform, based on DNA-based tests, has been recognized by the European Chemicals Agency (ECHA) as suitable for assessing allergenic reactivity. The company has also partnered with the US biotechnology company In vitro International (IVI) to distribute its allergen tests in the North American market. SenzaGen AB has developed a wide range of products that can be used in various sectors such as cosmetics, food, chemicals, and pharmaceuticals. AllergoDx™ is a test system used by the pharmaceutical and chemical industries to determine the allergenic reactivity of chemicals. GARD™ (Genomic Allergen Rapid Detection) is a rapid test used in the cosmetics and food industries to determine the allergenic reactivity of new products and avoid costly animal testing. GARDskin™ is a skin test used to determine the reactivity of substances that come into contact with the skin, primarily in the chemicals and pharmaceutical industries. Other products in the company's pipeline include GARDpotency™ and GARDair™, which are intended for assessing allergic reactions in industrial and occupational environments. SenzaGen AB has experienced significant growth in recent years and plans to expand its product range and strengthen its market position. The company's business model is based on selling tests and services to chemical, pharmaceutical, food, and cosmetic companies worldwide. Through its innovative technologies and willingness to collaborate with customers, the company has taken a leadership role in toxicology. SenzaGen AB is committed to an ethical and responsible corporate philosophy focused on sustainability and environmental protection. The company has clear goals to meet the growing demand for reliable and ethical testing methods to minimize the impact of chemicals on humans and the environment. SenzaGen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SenzaGen stock

FCF Conversion Rate (FCF/EBITDA) of SenzaGen is 86.80 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of SenzaGen changed from 77.65 % to 86.80 %, representing a 11.79% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) SenzaGen since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s SenzaGen with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — SenzaGen

All Key Metrics — SenzaGen